S. boulardii by Lallemand is now available from birth as both semi-finished and finished products for infants and young children, including ready-to-fill premixes, sachets and sticks, as well as orodispersible powders from six months of age with a specific composition. It can be combined with added-value ingredients suitable for paediatric populations, such as vitamins and prebiotics.
A new development combining S. boulardii and oral rehydration salts
Alongside this expanded paediatric offering, Lallemand Health Solutions has developed an
innovative solution which combines S. boulardii with an oral rehydration salts (ORS) premix in a single sachet. The ORS premix is specifically designed to follow World Health Organisation recommendations for salt composition and osmolarity, and the combined formulation is suitable for use from birth, providing manufacturers with a convenient, ready-to-go solution.
A time-tested yeast, continuously innovated
Lallemand Health Solutions has built extensive expertise around S. boulardii, mastering its development and production from lab to shelf, from strain management and fermentation to formulation and finished applications.
Over the years, Lallemand Health Solutions has continued to expand the possibilities of this time-tested probiotic yeast through new formats, applications and ingredient combinations.
In 2023, Lallemand Health Solutions introduced the first organic probiotic S. boulardii, offering a new option for brands developing certified organic dietary supplements.
The latest developments for paediatric populations continue this approach: applying Lallemand’s scientific, manufacturing and formulation expertise to broaden the possibilities of a probiotic yeast with more than 100 years of history.
More than 100 years of S. boulardii science
First isolated in 1923, S. boulardii has more than a century of history and has become the most extensively documented probiotic yeasts.
This long-standing scientific foundation also extends to paediatric populations, with more than 40 clinical studies involving over 5,800 infants and young children. Selected probiotics, including S.boulardii, are also recognised in the scientific literature and paediatric guidelines for their role in
the management of certain gastrointestinal conditions in children.¹
S. boulardii is a yeast with distinctive properties relevant to gastrointestinal applications. It tolerates the acidic environment of the gastrointestinal tract, survives and grows at human body temperature, and is naturally resistant to antibiotics. Its documented mechanisms of action include activity within the intestinal lumen, support of the intestinal environment and gut barrier, and interactions with the immune system.